FIELD: medicine.
SUBSTANCE: invention relates to a method of treating various diseases and/or pathological conditions caused by high aldosterone and/or excessive production of aldosterone, where diseases and/or pathological conditions represent heart failure, nephropathy and sleep apnoea syndrome, provided that hypertension is eliminated, which involves administering a therapeutically effective amount of a compound of formula [I], values of radicals in which are given in the claim.
.
EFFECT: technical result: a method of treating heart failure, nephropathy and sleep apnoea syndrome caused by high aldosterone and/or excessive production of aldosterone by novel compounds of formula [1].
11 cl, 44 tbl, 373 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL DISUBSTITUTED 1,2,4-TRIAZINE COMPOUND | 2015 |
|
RU2693624C2 |
| NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | 2015 |
|
RU2669938C2 |
| NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR ITS SALT | 2013 |
|
RU2632253C2 |
| NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | 2014 |
|
RU2655604C2 |
| SUBSTITUTED CONDENSED HETEROCYCLIC COMPOUND, METHOD OF PHARMACOLOGICAL EFFECT, METHOD OF INHIBITION OF 5-LIPOXYGENASE ACTIVITY, INHIBITION OF LIPID PEROXIDES PRODUCTION OR BLOOD SUGAR LEVEL DECREASE | 1998 |
|
RU2196141C2 |
| BENZOFURAN DERIVATIVES | 2003 |
|
RU2286344C2 |
| NOVEL BICYCLIC HETEROCYCLIC COMPOUND | 2009 |
|
RU2518073C2 |
| SPHINGOSINE-1-PHOSPHATE BINDING INHIBITOR | 2007 |
|
RU2395499C2 |
| HETEROCYCLIC COMPOUND | 2019 |
|
RU2815003C2 |
| CYNNAMIDE COMPOUND | 2005 |
|
RU2361872C2 |
